COVID-19
Tixagevimab/Cilgavimab Significantly Reduces SARS-CoV-2 Infections in Solid Organ Transplant Recipients
A recent study conducted at the Beth Israel Deaconess Medical Center has shed light on the effectiveness of tixagevimab/cilgavimab in preventing breakthrough SARS-CoV-2 infections in solid organ transplant (SOT) recipients. The research, which was published in the Transplantation Proceedings journal, demonstrates that the monoclonal antibodies can significantly reduce the